For instance, TP53-mutant and/or del(17p) CLL subclones are almost invariably selected under chemotherapy-based treatments (34, 94, 95), whereas this is often not the case with targeted therapy (47, 96). This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.